EVE Health Group Limited

As of June 30, 2026, EVE Health Group Limited carries a market capitalization of 6.69M, placing it among publicly traded companies globally. Its enterprise value stands at 5.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, EVE Health Group Limited has 352.33M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.80, and the price-to-book ratio stands at 1.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.73 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.46M versus a market cap of 6.69M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, EVE Health Group Limited maintains a current ratio of 4.28, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, EVE Health Group Limited posted a negative return on equity (ROE) of -50.42, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -45.01, reflecting losses generated across the asset base. Inventory turnover of 4.25 indicates how many times EVE Health Group Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 21, 2026, EVE Health Group Limited's stock has declined approximately 46.43% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.02.

Over the twelve months ended June 30, 2026, EVE Health Group Limited generated 1.15M in revenue and converted that into -1.89M in net income, yielding earnings per share of -0.01. EBITDA reached -1.77M, while operating income came in at -1.90M.

These figures are as of June 30, 2026. Total book value stands at 3.95M, with working capital of 1.08M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, EVE Health Group Limited posted a gross margin of 45.75, reflecting its pricing power and cost economics. The operating margin of -164.81 and net profit margin of -163.97 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -31.05, meaning EVE Health Group Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

EVE Health Group Limited's most recent stock split took place on June 12, 2025 with a 40:1 split ratio.

As of June 30, 2026, EVE Health Group Limited has an Altman Z-Score of -28.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.